---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024956"
form_type: "8-K"
ticker: "DMAC"
cik: "0001401040"
company_name: "DiaMedica Therapeutics Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:02:33.791700+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# DiaMedica CMO Lorianne Masuoka resigns; Julie Krop appointed as successor

## Summary
- Lorianne Masuoka resigned as CMO effective Aug 4, 2025 for personal reasons; separation agreement provides health benefits through Oct 2026.
- Julie Krop appointed as CMO effective Aug 11, 2025; Krop brings 20+ years experience, most recently CMO at PureTech Health.
- Krop previously CMO at Freeline Therapeutics and AMAG Pharmaceuticals; involved in preeclampsia drug development at AMAG.
- Krop will lead clinical development of DM199 for preeclampsia and acute ischemic stroke.

## SEC filing metadata
- accession: 0001437749-25-024956
- form_type: 8-K
- ticker: DMAC
- cik: 0001401040
- company_name: DiaMedica Therapeutics Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/0001437749-25-024956-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401040/000143774925024956/dmtp20250805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024956
- JSON: https://secwatch.observer/filing/0001437749-25-024956.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024956.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.